William Benton Jones
Net Worth
Last updated:
What is William Benton Jones net worth?
The estimated net worth of Dr. William Benton Jones is at least $1,158,345 as of 6 May 2024. He owns shares worth $99,495 as insider and has received compensation worth at least $1,058,850 in Corvus Pharmaceuticals, Inc..
What is the salary of William Benton Jones?
Dr. William Benton Jones salary is $352,950 per year as Senior Vice President of Pharmaceutical Devel. in Corvus Pharmaceuticals, Inc..
How old is William Benton Jones?
Dr. William Benton Jones is 59 years old, born in 1966.
What stocks does William Benton Jones currently own?
As insider, Dr. William Benton Jones owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | Senior Vice President of Pharmaceutical Devel. | 19,357 | $5.14 | $99,495 |
What does Corvus Pharmaceuticals, Inc. do?
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
William Benton Jones insider trading
Corvus Pharmaceuticals key executives
Corvus Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Peter A. Thompson FACP, M.D. (65) Co-Founder & Independent Director
- Dr. Richard A. Miller M.D. (74) Co-Founder, Pres, Chief Executive Officer & Chairman
- Dr. William Benton Jones (59) Senior Vice President of Pharmaceutical Devel.
- Mr. Leiv Lea (71) Chief Financial Officer